Published in Biol Psychiatry on May 23, 2007
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci (2008) 3.22
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology (2011) 2.70
Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology (2010) 2.31
mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology (2009) 1.80
Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov (2014) 1.51
Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav Pharmacol (2008) 1.43
Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? Curr Opin Neurobiol (2011) 1.35
Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology (2010) 1.34
Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology (2010) 1.30
Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken) (2011) 1.24
Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis (2013) 1.20
Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc Natl Acad Sci U S A (2008) 1.13
mGluR5 positive allosteric modulation enhances extinction learning following cocaine self-administration. Behav Neurosci (2011) 1.10
Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur J Pharmacol (2010) 1.07
Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses (2010) 1.06
Targeting glutamate synapses in schizophrenia. Trends Mol Med (2011) 1.06
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. ACS Med Chem Lett (2015) 1.00
Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules (2011) 0.99
Acute administration of typical and atypical antipsychotics reduces EEG γ power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in γ power. Int J Neuropsychopharmacol (2011) 0.93
Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. Behav Brain Res (2009) 0.93
Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorg Med Chem Lett (2015) 0.92
Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats. Neurobiol Learn Mem (2010) 0.90
Novel mGluR5 positive allosteric modulator improves functional recovery, attenuates neurodegeneration, and alters microglial polarization after experimental traumatic brain injury. Neurotherapeutics (2014) 0.87
Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1. Neuropharmacology (2012) 0.87
Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol (2012) 0.85
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol (2011) 0.83
mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptors by PKC dependent pathway. J Biomed Sci (2011) 0.83
mGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching/non-matching-to-sample task. Psychopharmacology (Berl) (2014) 0.82
Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology (Berl) (2012) 0.81
Dissociable effects of mGluR5 allosteric modulation on distinct forms of impulsivity in rats: interaction with NMDA receptor antagonism. Psychopharmacology (Berl) (2015) 0.80
The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology (Berl) (2011) 0.80
Pharmacological enhancement of mGluR5 facilitates contextual fear memory extinction. Learn Mem (2014) 0.79
Metabotropic glutamate receptors: potential drug targets for psychiatric disorders. Open Med Chem J (2010) 0.79
mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex. CNS Neurol Disord Drug Targets (2015) 0.77
The mGluR5 positive allosteric modulator CDPPB inhibits SO₂-induced protein radical formation and mitochondrial dysfunction through activation of Akt in mouse hippocampal HT22 cells. Cell Mol Neurobiol (2014) 0.77
Effects of D- and L-govadine on the disruption of touchscreen object-location paired associates learning in rats by acute MK-801 treatment. Psychopharmacology (Berl) (2015) 0.77
Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 positive allosteric modulator. J Psychopharmacol (2014) 0.75
Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorg Med Chem Lett (2015) 0.75
Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression. J Neural Transm (Vienna) (2015) 0.75
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry (2005) 9.23
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 8.10
Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry (1995) 5.59
Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry (1991) 5.36
Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 5.30
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry (2005) 3.74
A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther (2004) 2.83
Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem (1989) 2.75
Bursts and recurrences of bursts in the spike trains of spontaneously active striate cortex neurons. J Neurophysiol (1985) 2.70
Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry (1959) 2.66
The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry (1997) 2.63
Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem (2004) 2.46
D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry (1998) 2.36
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U S A (2004) 2.32
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology (1997) 2.20
A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther (2004) 2.17
Bringing order to the glutamate chaos in schizophrenia. Neuron (2003) 2.12
Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (1987) 2.08
Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science (1997) 2.01
Drugs, neurotransmitters, and schizophrenia. Science (1974) 2.00
Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology (1999) 1.97
NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 1.88
Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol (2005) 1.80
Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology (2004) 1.71
Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci (2000) 1.69
Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) (2004) 1.69
Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behav Neurosci (2003) 1.69
Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin (2004) 1.64
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry (1999) 1.63
Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry (2006) 1.62
(RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology (1997) 1.61
NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci (1996) 1.58
Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol (2002) 1.58
Selective activation of mesocortical DA system by stress. Nature (1976) 1.56
Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci (1998) 1.56
Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol (2004) 1.55
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry (2006) 1.49
Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord (2002) 1.49
Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport (1995) 1.46
Role of protein kinase C phosphorylation in rapid desensitization of metabotropic glutamate receptor 5. Neuron (1998) 1.39
Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther (2000) 1.39
Treatment of negative symptoms. Schizophr Bull (1985) 1.39
Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology (Berl) (2001) 1.38
Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus (2001) 1.35
Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry (2000) 1.33
Systemic and prefrontal cortical NMDA receptor blockade differentially affect discrimination learning and set-shift ability in rats. Behav Neurosci (2005) 1.33
The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl) (2004) 1.21
DHPG-induced LTD in area CA1 of juvenile rat hippocampus; characterisation and sensitivity to novel mGlu receptor antagonists. Neuropharmacology (1999) 1.20
Activation of metabotropic glutamate receptor mGlu5 on nuclear membranes mediates intranuclear Ca2+ changes in heterologous cell types and neurons. J Biol Chem (2003) 1.19
Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol (1990) 1.18
Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) (2005) 1.14
Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord (2002) 1.08
Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry (1978) 1.07
Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry (2002) 1.07
Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb Cortex (2005) 1.05
Functional metabotropic glutamate receptors on nuclei from brain and primary cultured striatal neurons. Role of transporters in delivering ligand. J Biol Chem (2005) 1.05
Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci (1998) 1.04
Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex (2004) 0.97
(S)-3,5-DHPG: a review. CNS Drug Rev (2002) 0.96
Activation of metabotropic glutamate 5 and NMDA receptors underlies the induction of persistent bursting and associated long-lasting changes in CA3 recurrent connections. J Neurosci (2003) 0.95
Glycine modulators in schizophrenia. Curr Opin Investig Drugs (2002) 0.88
Activation of group I metabotropic glutamate receptors enhances efficacy of glutamatergic inputs to neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci (2004) 0.88
NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol Biochem Behav (2002) 0.87
Psychiatric medication-induced obesity: treatment options. Obes Rev (2004) 0.86
Direct effects of metabotropic glutamate receptor compounds on native and recombinant N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A (1998) 0.84
The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices. Eur J Pharmacol (2006) 0.82
Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. J Clin Exp Psychopathol (1955) 0.79
Hyperglycemia with antipsychotic treatment. Curr Diab Rep (2004) 0.77
The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.76
NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci (2007) 4.35
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol (2006) 2.73
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U S A (2004) 2.32
Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology (2004) 1.71
Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behav Neurosci (2003) 1.69
Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol Psychiatry (2013) 1.67
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain (2011) 1.55
Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol (2004) 1.55
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav Pharmacol (2008) 1.43
Progression of cellular adaptations in medial prefrontal and orbitofrontal cortex in response to repeated amphetamine. J Neurosci (2006) 1.38
Differential tonic influence of lateral habenula on prefrontal cortex and nucleus accumbens dopamine release. Eur J Neurosci (2008) 1.36
Rule learning and reward contingency are associated with dissociable patterns of dopamine activation in the rat prefrontal cortex, nucleus accumbens, and dorsal striatum. J Neurosci (2006) 1.35
Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry (2002) 1.34
Systemic and prefrontal cortical NMDA receptor blockade differentially affect discrimination learning and set-shift ability in rats. Behav Neurosci (2005) 1.33
Analysis and design of behavioral experiments to characterize population learning. J Neurophysiol (2004) 1.26
Anterior cingulate neurons represent errors and preparatory attention within the same behavioral sequence. J Neurosci (2009) 1.23
Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology (2002) 1.23
Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology (2003) 1.22
Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs. J Neurosci (2012) 1.18
Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc Natl Acad Sci U S A (2008) 1.13
The neurobiology of adolescence: changes in brain architecture, functional dynamics, and behavioral tendencies. Neurosci Biobehav Rev (2011) 1.13
Divergent plasticity of prefrontal cortex networks. Neuropsychopharmacology (2007) 1.12
Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry (2005) 1.09
Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry (2005) 1.08
Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur J Pharmacol (2010) 1.07
Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry (2012) 1.07
Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb Cortex (2005) 1.05
Preparatory attention relies on dynamic interactions between prelimbic cortex and anterior cingulate cortex. Cereb Cortex (2012) 1.04
Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann Neurol (2008) 1.03
Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging (2002) 1.03
Adolescents exhibit behavioral differences from adults during instrumental learning and extinction. Behav Neurosci (2010) 1.03
Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging (2003) 1.01
Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans. J Cereb Blood Flow Metab (2012) 1.01
Coordinated activity of ventral tegmental neurons adapts to appetitive and aversive learning. PLoS One (2012) 1.00
Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380. Synapse (2003) 1.00
Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition. Eur J Pharmacol (2010) 0.98
The influence of NMDA and GABA(A) receptors and glutamic acid decarboxylase (GAD) activity on attention. Psychopharmacology (Berl) (2012) 0.96
Reduced presynaptic dopamine activity in adolescent dorsal striatum. Neuropsychopharmacology (2013) 0.96
Striatum processes reward differently in adolescents versus adults. Proc Natl Acad Sci U S A (2012) 0.95
Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol Psychiatry (2006) 0.94
Following the genes: a framework for animal modeling of psychiatric disorders. BMC Biol (2011) 0.94
Stimulus-specific plasticity of prefrontal cortex dopamine neurotransmission. J Neurochem (2004) 0.94
The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology (2004) 0.93
The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway. Br J Pharmacol (2006) 0.93
Reduced neuronal inhibition and coordination of adolescent prefrontal cortex during motivated behavior. J Neurosci (2011) 0.92
Differential representation of Pavlovian-instrumental transfer by prefrontal cortex subregions and striatum. Eur J Neurosci (2009) 0.90
Asymmetric synthesis of (+)-(S,S)-reboxetine via a new (S)-2-(hydroxymethyl)morpholine preparation. Org Lett (2005) 0.89
Do endogenous opioids contribute to the bradycardia of rats with obstructive cholestasis? Fundam Clin Pharmacol (2002) 0.88
Distinct patterns of plasticity in prefrontal cortex neurons that encode slow and fast responses to stress. Eur J Neurosci (2006) 0.87
Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res (2002) 0.86
Advancing drug discovery for schizophrenia. Ann N Y Acad Sci (2011) 0.86
Distinct prestimulus and poststimulus activation of VTA neurons correlates with stimulus detection. J Neurophysiol (2013) 0.86
NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Synapse (2002) 0.86
Differences in response initiation and behavioral flexibility between adolescent and adult rats. Behav Neurosci (2013) 0.86
Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology (2003) 0.85
Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion. Psychopharmacology (Berl) (2010) 0.84
Sex and estrus cycle differences in the modulatory effects of morphine on seizure susceptibility in mice. Epilepsia (2004) 0.83
Putative γ-aminobutyric acid neurons in the ventral tegmental area have a similar pattern of plasticity as dopamine neurons during appetitive and aversive learning. Eur J Neurosci (2010) 0.83
The effects of adenosine receptor agonists and antagonists on morphine state-dependent memory of passive avoidance. Neurobiol Learn Mem (2002) 0.83
Distinct contributions of glutamate receptor subtypes to cognitive set-shifting abilities in the rat. Ann N Y Acad Sci (2003) 0.82
Improved working memory but no effect on striatal vesicular monoamine transporter type 2 after omega-3 polyunsaturated fatty acid supplementation. PLoS One (2012) 0.81
Glutamatergic animal models of schizophrenia. Curr Pharm Des (2012) 0.80
Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089. J Pharmacol Exp Ther (2010) 0.80
Decreased Beta(2)*-nicotinic acetylcholine receptor availability after chronic ethanol exposure in nonhuman primates. Synapse (2010) 0.80
Dopamine and serotonin transporter availability in chronic heroin users: a [¹²³I]β-CIT SPECT imaging study. Psychiatry Res (2010) 0.80
Adrenoceptor mechanisms underlying imipramine-induced memory deficits in rats. J Psychopharmacol (2003) 0.79
Dopamine receptor mechanism(s) and morphine tolerance in mice. J Psychopharmacol (2002) 0.79
The effect of L-NAME and L-arginine on impairment of memory formation and state-dependent learning induced by morphine in mice. Psychopharmacology (Berl) (2003) 0.78
Research strategies and priorities to improve the lives of people with schizophrenia: executive summary of the Ernst Strüngmann Forum on schizophrenia. Schizophr Bull (2014) 0.77
Lithium inhibits the modulatory effects of morphine on susceptibility to pentylenetetrazole-induced clonic seizure in mice: involvement of a nitric oxide pathway. Brain Res (2004) 0.77
Chemical fate of the nicotinic acetylcholinergic radiotracer [123I]5-IA-85380 in baboon brain and plasma. Nucl Med Biol (2006) 0.77
Intestinal inflammation alters the susceptibility to pentylenetetrazole-induced seizure in mice. J Gastroenterol Hepatol (2004) 0.77
Microwave-induced nucleophilic [18F]fluorination on aromatic rings: synthesis and effect of halogen on [18F]fluoride substitution of meta-halo (F, Cl, Br, I)-benzonitrile derivatives. Appl Radiat Isot (2008) 0.77
Convenient synthesis of 18F-radiolabeled R-(-)-N-n-propyl-2-(3-fluoropropanoxy-11-hydroxynoraporphine. J Labelled Comp Radiopharm (2014) 0.77
Modulation of cholestasis-induced antinociception by CCK receptor agonists and antagonists. Eur Neuropsychopharmacol (2002) 0.76
Synthesis of cyclopentadienyltricarbonyl rhenium phenyltropanes by double ligand transfer: organometallic ligands for the dopamine transporter. Bioconjug Chem (2002) 0.76
Synthesis, receptor potency, and selectivity of halogenated diphenylpiperidines as serotonin 5-HT2A ligands for PET or SPECT brain imaging. J Med Chem (2002) 0.76
Synthesis and monoamine transporter affinity of 3'-analogs of 2-beta-carbomethoxy-3-beta-(4'-iodophenyl)tropane (beta-CIT). Bioorg Med Chem Lett (2004) 0.76
Synthesis and receptor binding studies of halogenated N,N-dialkylel-(2-phenyl-1H-indol-3-yl)glyoxylamides to visualize peripheral benzodiazepine receptors with SPECT or PET. Bioorg Med Chem (2006) 0.75
The role of nitric oxide in the proconvulsant effect of delta-opioid agonist SNC80 in mice. Neurosci Lett (2002) 0.75
Iodine-123 labeled reboxetine analogues for imaging of noradrenaline transporter in brain using single photon emission computed tomography. Synapse (2012) 0.75
The role of alpha-adrenoceptors in the amnestic effect of intracerebroventricular dexamethasone. Pharmacol Res (2002) 0.75
Rearrangement of a mesylate tropane intermediate in nucleophilic substitution reactions. Synthesis of aza-bicyclo[3.2.1]octane and aza-bicyclo[3.2.2]nonane ethers, imides, and amines. J Org Chem (2002) 0.75
In vivo evaluation of [¹²³I]mZIENT as a SPECT radioligand for the serotonin transporter. Nucl Med Biol (2012) 0.75
Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER. Synapse (2012) 0.75
Radiosynthesis of [18F] N-(3-Fluoropropyl)-2-beta-Carbomethoxy-3-beta-(4-Bromophenyl) Nortropane and the regional brain uptake in non human primate using PET. Nucl Med Biol (2004) 0.75
Automated one-step radiosynthesis of the CB1 receptor imaging agent [(18) F]MK-9470. J Labelled Comp Radiopharm (2014) 0.75
Mediation of nitric oxide in inhibitory effect of morphine against electroshock-induced convulsions in mice. Pharmacol Biochem Behav (2003) 0.75
Inhibition by immunophilin ligands of morphine-induced tolerance and dependence in guinea pig ileum. Eur J Pharmacol (2003) 0.75
Biodistribution and dosimetry of ¹²³I-mZIENT: a novel ligand for imaging serotonin transporters. Eur J Nucl Med Mol Imaging (2012) 0.75
The synergistic anticonvulsant effect of agmatine and morphine: possible role of alpha 2-adrenoceptors. Epilepsy Res (2005) 0.75